Your Yourlocation: Home > Tiotropium bromide(136310-93-5) can be effective relaxation of bronchial smooth muscle

In the Maesen dose-response study, tiotropium bromide(136310-93-5) was able to effectively relax bronchial smooth muscle in the range of 10-80 μg per day. Littner et al included 169 cases of COPD patients, in the 415 ~ 36μg dose range, divided into four dose groups and on

According to the treatment group, 28d. The FEV1 trough of each treatment group increased about 0.1L from the baseline and reached a stable level. Compared with the control group, the FEV1 increased from 0.12 to 0.2L at 6 hours after the last dose, and there was no significant difference between the different dose groups. Therefore, later studies have used tiotropium bromide(136310-93-5) daily dose of 8μg. At the end of the trial, tiotropium was discontinued and returned to the pre-study level after about 3 weeks of baseline, indicating a continuation of the drug.

The United States completed a phase Ia tiotropium bromide(136310-93-5) versus a placebo-controlled trial; Europe completed the control trial of tiotropium and ipratropium bromide in cycle 1a; two additional 6-month trials compared thiazide Tobramide and salmeterol, tiotropium and placebo.

In two trials with a duration of 1 year, 18 μg of tiotropium bromide(136310-93-5) was given once daily to patients with moderate to severe COPD; one of the control subjects was given placebo and the other administered 4 times daily Ipratropium bromide, each 40μg, selected patients were 921 cases and 535 cases. The primary endpoint of both trials was FEV1 trough, and secondary end points were shortness of breath index, health status, deterioration of COPD, and adverse events. Baseline FEV1 values were similar in the two trial groups. After 8 days of treatment, the FEV1 trough in the treatment group increased 011 L from baseline. In both studies, the FEV1 trough of the treatment group remained at the 8th day after 8 days until the end of the trial, while the FEV1 trough of the control group was the same as or lower than the baseline value. At the end of the 1a trial, the FEV1 trough of the treatment group was 0.15 L higher than the control group.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved